Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:02:36 2024-06-20 EDT			5-day change	1st Jan Change
93.44 ^CHF	-0.51%		-0.71%	+10.27%

11:10am	Novartis: towards the filing of a buyout offer for MorphoSys	CF
10:20am	MorphoSys Set to Delist Following Acquisition by Novartis	MT

NOVARTIS AG : UBS reiterates its Buy rating

May 31, 2024 at 02:19 pm

UBS analyst Matthew Weston maintains his Buy rating on the stock. The target price is unchanged at CHF 108.

Latest news about Novartis AG

Novartis: towards the filing of a buyout offer for MorphoSys	05:10am	CF
MorphoSys Set to Delist Following Acquisition by Novartis	04:20am	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	04:18am	MT
Biotech company Morphosys will soon disappear from the stock exchange	03:57am	RE
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	06-14	MT
Nkarta, Inc. Appoints George Vratsanos as Board of Directors	06-13	CI
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment	06-13	CI
NOVARTIS AG : JP Morgan reiterates its Neutral rating	06-11	ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	06-07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	06-07	MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation	06-06	MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	06-06	RE
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe	06-06	DJ
Novartis and others face Italy antitrust probe over eye drug	06-06	RE
Three newcomers to the MDax - Rational, TUI and Traton move up	06-06	RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout	06-05	DJ
The odds of rates getting cut in 2024 may be better than you think	06-05
NOVARTIS AG : Deutsche Bank maintains a Buy rating	06-05	ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation	06-04	MT
NOVARTIS AG : JP Morgan remains Neutral	06-03	ZD
NOVARTIS AG : Buy rating from Goldman Sachs	06-03	ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO	06-03	CF
SMA Solar and Morphosys are about to leave the MDax	06-03	RE
NOVARTIS AG : UBS gives a Buy rating	06-03	ZD

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-06-19 - JP Morgan European Healthcare Conference

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.2 USD

Average target price

110.3 USD

Spread / Average Target

+3.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+10.27%	217B
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+41.25%	631B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.72%	243B
ROCHE HOLDING AG	+2.17%	228B
AMGEN INC.	+6.24%	164B
PFIZER, INC.	-4.79%	155B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : UBS reiterates its Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals